Breadcrumb navigation
Infectious Diseases
Next-generation prophylactic vaccines combining T cell and B cell epitope prediction for broad, durable protection against evolving pathogens. And therapeutic vaccines targeted at clearing chronic infection.
Infectious Disease Vaccine Development
Effective vaccines against infectious diseases may need T cell immunity, neutralizing antibodies, or both. Our platform supports both approaches, enabling optimized vaccine designs for any pathogen.
Challenges in Infectious Disease Vaccine Development
-
Pathogen diversity and immune escape – Pathogens vary across strains and evolve under immune pressure, so epitopes selected against one variant may not hold against the next.
-
Population coverage – HLA types vary widely among individuals and across populations, so a target set that protects one population can leave another uncovered.
-
Supporting antibody responses with helper T cells – Identifying an antibody target alone does not ensure a strong, lasting response. The immunogen must display the target effectively and provide suitable epitopes that can be presented to helper T cells.
-
From epitope to construct – A selected epitope still has to be built into an immunogen that is stable, manufacturable, and can be delivered effectively.
Our Approach
We turn large-scale pathogen sequence data into a ranked, population-aware set of T cell and B cell targets that aid in the design and delivery of immunogens. We select epitopes that are both immunogenic and conserved across strains, which reduces the risk of escape, and we support designs that rely on T cell immunity, antibody responses, or both.
B cell Antibody Target Discovery & Immunogen Design
Designed for vaccines and immunotherapies that rely on antibody responses, including integrated strategies where CD4+ helper T cells enhance and sustain humoral immunity.
Our platform combines AI-driven conformational epitope discovery with computational structural biology to identify, optimize, and engineer clinically relevant antibody targets and immunogen constructs.
Capabilities:
- AI-guided conformational B cell epitope identification
- Structural modeling of antigen–antibody interactions
- Conservation analysis for escape-resistant target selection
- Protein engineering and immunogen design
- CD4+ helper T cell support optimization
- Integrated construct design combining B cell epitopes with HLA class II helper epitopes
By integrating epitope prediction, structural modeling, and immunogen engineering into a unified workflow, NEC Bio enables the rational development of next-generation vaccine and therapeutic constructs with enhanced scientific relevance and translational potential.
Learn more about our B cell epitope prediction technology
T cell Target Discovery and Immunogen Design
Vaccines that rely on cellular immunity, including broad-spectrum prophylactic and therapeutic vaccines against chronic infection.
Capabilities:
- T cell epitope mining across the pathogen proteome
- Class I and Class II epitope prediction
- Data-driven identification of vaccine elements
- HLA population response modeling
- Construct optimization
Learn more about our T cell epitope prediction technology.
Case Studies and Technology
Betacorona: broad-spectrum coronavirus targets
A pan-betacoronavirus T cell target set identified from conserved regions across strains, built for durable protection against evolving variants.
BERTMHC: improved MHC–peptide class II interaction prediction
Introduces a deep learning approach that optimizes neoantigen discovery by accurately predicting HLA class II-peptide interactions